Navigation Links
Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
Date:12/8/2008

ential for patients to reach important clinical milestones faster."

Gleevec(R) (imatinib mesylate) tablets* is the standard treatment for Ph+ CML and rapidly transformed the treatment of CML when it was introduced in 2001. An ongoing Phase III trial called ENESTnd (Evaluating Nilotinib Efficacy in Clinical Trials of Newly Diagnosed Ph+ CML Patients) is evaluating Tasigna vs. Gleevec in newly diagnosed patients and is now fully accrued. Data from ENESTnd will be reported once available.

"Building on the wealth of scientific and clinical knowledge we have gained with Gleevec, Novartis strives to continually uncover novel approaches to help Ph+ CML patients achieve the best long-term outcomes," said David Epstein, President and CEO, Novartis Oncology.

Tasigna is a tyrosine kinase inhibitor approved for the treatment of adult Ph+ CML patients in the chronic or accelerated phases who are resistant or intolerant to prior treatment including Gleevec. Tasigna was specifically designed to inhibit Bcr-Abl, the key cause and driver of Ph+ CML and its mutations. The Philadelphia chromosome is found in nearly all patients with CML.

Study results

The first study, conducted by the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA), is an ongoing, open-label, single-stage, multicenter Phase II clinical trial, designed to evaluate the therapeutic efficacy and safety of Tasigna 800 mg/day as a first-line treatment. Seventy-three patients with newly diagnosed Ph+ CML in early chronic phase are enrolled in the trial. After six months of treatment, 96% of patients had achieved CCyR(2).

In addition, 74% of patients achieved MMR, defined as Bcr-Abl/Abl ratio < 0.1%. The percentage of patients achieving this level of response rapidly increased after one month of treatment. Adverse reactions were manageable with dose adaptations. The incidence of an
'/>"/>

SOURCE Novartis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... with Turner ... ... Norditropin(R) (somatropin [rDNA origin] injection) received,approval from the U.S. Food and ... with Turner syndrome. Turner,syndrome is a rare chromosomal condition caused by ...
... NeurogesX, Inc.,(Nasdaq: NGSX ) announced today ... second Phase 3 clinical trial of its lead ... sensory polyneuropathy,(HIV-DSP). NGX-4010 is a dermal patch designed ... trials demonstrated that a,single, 30- or 60-minute treatment ...
Cached Medicine Technology:Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 2Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 3Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 4Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 5Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 6NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 2NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 3NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 4
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... LunaDress.co.uk has updated its blog to provide professional shopping tips on ... models at LunaDress.co.uk come with big discounts, up to 80 percent ... turn out to be a most exciting memory and can show ... surprise to a wedding. On the updated fashion blog, ladies can ... a big day . , Going out with friends to a ...
(Date:12/25/2014)... 24, 2014 (HealthDay News) -- Among early stage breast ... than half of one percent will eventually develop leukemia ... reveals. The finding comes from a review of ... and 2007, and it suggests that the risk for ... experts had previously thought. "The frequency of bone ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... AMERIGROUP,Corporation (NYSE: AGP ) today announced that ... Conference on November 13 in Phoenix,Arizona., A live ... at 4:00 p.m. Eastern Time, can be accessed on ... A replay will,be available for 30 days, and can ...
... LOS ANGELES, Oct. 30 Members of SEIU ... collective bargaining,agreements that will make improvements for hundreds ... several California nursing homes., In all, seven ... wage increases of $1.50/hr over three years, employer ...
... age of disease onset and nerve cell death , , ... genes may be linked to the most common form ... team, from Massachusetts General Hospital-MassGeneral Institute for Neurological Disease ... families with a history of the devastating neurological disorder. ...
... Medical, Inc.,(Nasdaq: ATSI ), manufacturer and marketer ... it has received U.S. Food,and Drug Administration (FDA) ... http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), This is the Company,s ... market. Based on the precept that ,Form Follows ...
... WellPoint,s commercial marketing,team was awarded a silver ... its innovative campaign, "Ecosphere -- Simple is more ... Awards competition is the only international,award that honors ... response results., WellPoint,s campaign, conducted through its ...
... AGA Medical Holdings ("AGA,Medical", "AGA") announced today its ... Court in the Netherlands related to a proceeding,brought ... lawsuit,sought invalidity and/or non-infringement declarations related to AGA,Medical,s ... its European patents,for intravascular occlusion devices and the ...
Cached Medicine News:Health News:Scientists Spot 4 New Alzheimer's Genes 2Health News:ATS Medical Announces FDA Approval of the ATS 3f Aortic Bioprosthesis 2Health News:ATS Medical Announces FDA Approval of the ATS 3f Aortic Bioprosthesis 3Health News:ATS Medical Announces FDA Approval of the ATS 3f Aortic Bioprosthesis 4Health News:WellPoint Awarded Prestigious International Marketing Award 2Health News:AGA Medical to Appeal Ruling by Dutch Court in Lawsuit With Occlutech GmbH 2
... Blot is an FDA approved confirmatory test ... fluid sample. Repeatedly reactive results of initial ... HIV-1 Microelisa System can be confirmed with ... the same OraSure sample. The OraSure HIV-1 ...
Prognosis / Patient Management. HIV-1 Viral Load Assay. NucliSens HIV-1 QT covers the entire dynamic range of viral load testing from a single patient sample, without reflex testing or thermalcycli...
... genome of the Human Immunodeficiency Virus (HIV-1) ... in response to anti-viral drug treatment. Some ... render the virus resistant to the action ... the treatment.,The detection of mutations in HIV-1 ...
EIA for Donor Screening. Synthetic peptide Enzyme Immunoassay (EIA) for the detection of antibodies to Human Immunodeficiency Virus Types 1 and/or 2,(HIV-1 and HIV-2) in human serum, plasma or ca...
Medicine Products: